Specifičnost i osjetljivost VEGF u dijagnostici i terapiji tumora u stručnoj literaturi
1. Będkowska GE, Gacuta E, Zbucka-Krętowska M, et al. Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer. J Clin Med. 2021,10(22): 5452.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624052/
2. Zajkowska M, Głażewska EK, Będkowska GE, Chorąży P, Szmitkowski M, Ławicki S. Diagnostic Power of Vascular Endothelial Growth Factor and Macrophage Colony-Stimulating Factor in Breast Cancer Patients Based on ROC Analysis. Mediators Inflamm. 2016, 2016:5962946.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947496/
3. Zajkowska, M., Lubowicka, E., Fiedorowicz, W.et al. Human Plasma Levels of VEGF-A, VEGF-C, VEGF-D, their Soluble Receptor – VEGFR-2 and Applicability of these Parameters as Tumor Markers in the Diagnostics of Breast Cancer. Pathol Oncol Res. 2019, 25:1477–1486.
https://link.springer.com/article/10.1007/s12253-018-0527-0
4. Hamdy MN, Shaheen KY, Awad MAM, Barakat EMF, Shalaby SI, Gupta N, Gupta V . Vascular endothelial growth factor (VEGF) as a biochemical marker for the diagnosis of hepatocellular carcinoma (HCC).Clinical practice. 2020, 17(1): 1441 – 1453
https://www.openaccessjournals.com/articles/vascular-endothelial-growth-factor-vegf-as-a-biochemical-marker-for-the-diagnosis-of-hepatocellular-carcinoma-hcc-13154.html
5. Wardhani AK, Samsuria IK, Hendrianingtyas M, Limijadi EKS, Triwardhani R. Diagnostic Value of Vascular Endothelial Growth Factor C (VEGF-C) and CA 15-3 in Breast Cancer. Journal of Biomedicine and Translational Research. 2021, 7(3): 97-104.
https://ejournal2.undip.ac.id/index.php/jbtr/article/view/11681
7.Ławicki S, Zajkowska M, Głażewska E, Będkowska G, Szmitkowski M. Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer. Onco Targets Ther. 2016, 9:911-919.
8. Sidorkiewicz I, Zbucka-Krętowska M, Zaręba K, et al. Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers. BMC Cancer. 2019, 19: 398.
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5558-8
9. Lai Y, Wang X, Zeng T, Xing S, Dai S, Wang J, Chen S, Li X, Xie Y, Zhu Y, Liu W. Serum VEGF levels in the early diagnosis and severity assessment of non-small cell lung cancer. J Cancer. 2018, 9(9):1538-1547.
https://www.jcancer.org/v09p1538.htm
10. Ławicki L, Zajkowska M, Głażewska EK, Będkowska GE, Szmitkowski M. Plasma levels and diagnostic utility of VEGF, MMP-2 and TIMP-2 in the diagnostics of breast cancer patients. Biomarkers. 2017, 22(2):157-164.
https://www.tandfonline.com/doi/abs/10.1080/1354750X.2016.1252955
11. Kut, C., Mac Gabhann, F. & Popel, A. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer. 2007, 97: 978–985.
https://www.nature.com/articles/6603923
12. Chen, Y., Mathy, N. W., & Lu, H. (2018). The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non‑small cell lung cancer (Review). Molecular medicine reports, 17(6), 8019–8030.
https://doi.org/10.3892/mmr.2018.8922
13.Będkowska, G. E., Gacuta, E., Zbucka-Krętowska, M., Ławicki, P., Szmitkowski, M., Lemancewicz, A., Motyka, J., Kobus, A., Chorąży, M., Paniczko, M., & Ławicki, S. (2021). Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer. Journal of clinical medicine, 10(22), 5452.
https://doi.org/10.3390/jcm10225452
14.Zajkowska, M., Głażewska, E. K., Będkowska, G. E., Chorąży, P., Szmitkowski, M., & Ławicki, S. (2016). Diagnostic Power of Vascular Endothelial Growth Factor and Macrophage Colony-Stimulating Factor in Breast Cancer Patients Based on ROC Analysis. Mediators of inflammation, 2016, 5962946.
https://doi.org/10.1155/2016/5962946
15. Zajkowska, M., Lubowicka, E., Fiedorowicz, W. et al. Human Plasma Levels of VEGF-A, VEGF-C, VEGF-D, their Soluble Receptor – VEGFR-2 and Applicability of these Parameters as Tumor Markers in the Diagnostics of Breast Cancer. Pathol. Oncol. Res. 25, 1477–1486 (2019).
https://doi.org/10.1007/s12253-018-0527-0
16.Hamdy, M & Shaheen, Karim & Barakat, Eman & Shalaby, S & Gupta, Neelima & Gupta, Varsha & Shahu, Chhatrapati. (2020). Vascular endothelial growth factor (VEGF) as a biochemical marker for the diagnosis of hepatocellular carcinoma (HCC).
https://www.openaccessjournals.com/articles/vascular-endothelial-growth-factor-vegf-as-a-biochemical-marker-for-the-diagnosis-of-hepatocellular-carcinoma-hcc-13154.html
17. Wardhani, A. K., Samsuria, I. K., Hendrianingtyas, M., Limijadi, E. K. S., & Triwardhani, R. (2021). Diagnostic Value of Vascular Endothelial Growth Factor C (VEGF-C) and CA 15-3 in Breast Cancer. Journal of Biomedicine and Translational Research, 7(3), 97-104.
https://doi.org/10.14710/jbtr.v7i3.11681
18. Ruangrat, Pritsana.(2020). Detecting VEGF tumor markers in blood for early diagnosis of lung cancer. Research Prince of Songkla University
https://rdo.psu.ac.th/en/index.php/features/305-detecting-vegf-tumor-markers-in-blood-for-early-diagnosis-of-lung-cancer
19. Ławicki S, Zajkowska M, Głażewska E, Będkowska G, Szmitkowski M. Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer. Onco Targets Ther. 2016;9:911-919
https://doi.org/10.2147/OTT.S99959
20. Sidorkiewicz, I., Zbucka-Krętowska, M., Zaręba, K. et al. Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers. BMC Cancer 19, 398 (2019).
https://doi.org/10.1186/s12885-019-5558-8
21. Lai Y, Wang X, Zeng T, Xing S, Dai S, Wang J, Chen S, Li X, Xie Y, Zhu Y, Liu W. Serum VEGF levels in the early diagnosis and severity assessment of non-small cell lung cancer. J Cancer 2018; 9(9):1538-1547. doi:10.7150/jca.23973.
https://www.jcancer.org/v09p1538.htm
22. (2017) Plasma levels and diagnostic utility of VEGF, MMP-2 and TIMP-2 in the diagnostics of breast cancer patients, Biomarkers, 22:2, 157-164, DOI: 10.1080/1354750X.2016.1252955
https://pubmed.ncbi.nlm.nih.gov/27775427/
23. Kut, C., Mac Gabhann, F. & Popel, A. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 97, 978–985 (2007).
https://doi.org/10.1038/sj.bjc.6603923
24. Chen, Y., Mathy, N.W., & Lu, H. (2018). The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non‑small cell lung cancer (Review). Molecular Medicine Reports, 17, 8019-8030.
https://doi.org/10.3892/mmr.2018.8922
25. Dbouk, Hashem & Tawil, Ayman & Nasr, Fahd & Kandakarjian, Loucine & Abou Merhi, Raghida. (2007). Significance of CEA and VEGF as Diagnostic Markers of Colorectal Cancer in Lebanese Patients. The open clinical cancer journal. 1. 1-5. 10.2174/1874189400701010001.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2490598/
26. Parikh, A. A., & Ellis, L. M. (2004). The vascular endothelial growth factor family and its receptors. Hematology/oncology clinics of North America, 18(5), 951–vii.
https://doi.org/10.1016/j.hoc.2004.06.004
27. Nagy, J. A., Vasile, E., Feng, D., Sundberg, C., Brown, L. F., Detmar, M. J., Lawitts, J. A., Benjamin, L., Tan, X., Manseau, E. J., Dvorak, A. M., & Dvorak, H. F. (2002). Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. The Journal of experimental medicine, 196(11), 1497–1506.
https://doi.org/10.1084/jem.20021244
28. Reinmuth, N., Parikh, A. A., Ahmad, S. A., Liu, W., Stoeltzing, O., Fan, F., Takeda, A., Akagi, M., & Ellis, L. M. (2003). Biology of angiogenesis in tumors of the gastrointestinal tract. Microscopy research and technique, 60(2), 199–207.
https://doi.org/10.1002/jemt.10258
29. Lee, J. C., Chow, N. H., Wang, S. T., & Huang, S. M. (2000). Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. European journal of cancer (Oxford, England : 1990), 36(6), 748–753.
https://doi.org/10.1016/s0959-8049(00)00003-4
30. Takahashi, Y., Kitadai, Y., Bucana, C. D., Cleary, K. R., & Ellis, L. M. (1995). Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer research, 55(18), 3964–3968.
https://pubmed.ncbi.nlm.nih.gov/7664263/
31.Minagawa, N., Nakayama, Y., Hirata, K., Onitsuka, K., Inoue, Y., Nagata, N., & Itoh, H. (2002). Correlation of plasma level and immunohistochemical expression of vascular endothelial growth factor in patients with advanced colorectal cancer. Anticancer research, 22(5), 2957–2963.
32.Chin, K. F., Greenman, J., Reusch, P., Gardiner, E., Marme, D., & Monson, J. R. (2003). Vascular endothelial growth factor and soluble Tie-2 receptor in colorectal cancer: associations with disease recurrence. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 29(6), 497–505.
https://doi.org/10.1016/s0748-7983(03)00056-8
33 .Takahashi, Y., Cleary, K. R., Mai, M., Kitadai, Y., Bucana, C. D., & Ellis, L. M. (1996). Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2(10), 1679–1684.
https://pubmed.ncbi.nlm.nih.gov/9816116/
34.Maeda, K., Kang, S. M., Onoda, N., Ogawa, M., Kato, Y., Sawada, T., & Chung, K. H. (1999). Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma. Cancer, 86(4), 566–571.
https://doi.org/10.1002/(sici)1097-0142(19990815)86:4<566::aid-cncr4>3.0.co;2-1
35.Fujimoto, K., Hosotani, R., Wada, M., Lee, J. U., Koshiba, T., Miyamoto, Y., Tsuji, S., Nakajima, S., Doi, R., & Imamura, M. (1998). Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. European journal of cancer (Oxford, England : 1990), 34(9), 1439–1447.
https://doi.org/10.1016/s0959-8049(98)00069-0
36.Ikeda, N., Adachi, M., Taki, T., Huang, C., Hashida, H., Takabayashi, A., Sho, M., Nakajima, Y., Kanehiro, H., Hisanaga, M., Nakano, H., & Miyake, M. (1999). Prognostic significance of angiogenesis in human pancreatic cancer. British journal of cancer, 79(9-10), 1553–1563.
https://doi.org/10.1038/sj.bjc.6690248
37. Adams, J., Carder, P. J., Downey, S., Forbes, M. A., MacLennan, K., Allgar, V., Kaufman, S., Hallam, S., Bicknell, R., Walker, J. J., Cairnduff, F., Selby, P. J., Perren, T. J., Lansdown, M., & Banks, R. E. (2000). Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer research, 60(11), 2898–2905.
https://pubmed.ncbi.nlm.nih.gov/10850435/
38. Berns, E. M., Klijn, J. G., Look, M. P., Grebenchtchikov, N., Vossen, R., Peters, H., Geurts-Moespot, A., Portengen, H., van Staveren, I. L., Meijer-van Gelder, M. E., Bakker, B., Sweep, F. C., & Foekens, J. A. (2003). Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 9(4), 1253–1258.
39.Manders, P., Beex, L. V., Tjan-Heijnen, V. C., Geurts-Moespot, J., Van Tienoven, T. H., Foekens, J. A., & Sweep, C. G. (2002). The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. British journal of cancer, 87(7), 772–778.
https://doi.org/10.1038/sj.bjc.6600555
40. Desruisseau, S., Palmari, J., Giusti, C., Romain, S., Martin, P. M., & Berthois, Y. (2004). Clinical relevance of amphiregulin and VEGF in primary breast cancers. International journal of cancer, 111(5), 733–740.
https://doi.org/10.1002/ijc.20312
41.Cooper, B. C., Ritchie, J. M., Broghammer, C. L., Coffin, J., Sorosky, J. I., Buller, R. E., Hendrix, M. J., & Sood, A. K. (2002). Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 8(10), 3193–3197.
https://pubmed.ncbi.nlm.nih.gov/12374688/
42.Alvarez Secord, A., Sayer, R., Snyder, S. A., Broadwater, G., Rodriguez, G. C., Berchuck, A., & Blackwell, K. (2004). The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer. Gynecologic oncology, 94(1), 74–79.
https://doi.org/10.1016/j.ygyno.2004.03.043
43. Duque, J. L., Loughlin, K. R., Adam, R. M., Kantoff, P. W., Zurakowski, D., & Freeman, M. R. (1999). Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology, 54(3), 523–527.
https://doi.org/10.1016/s0090-4295(99)00167-3
44. George, D. J., Halabi, S., Shepard, T. F., Vogelzang, N. J., Hayes, D. F., Small, E. J., Kantoff, P. W., & Cancer and Leukemia Group B 9480 (2001). Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clinical cancer research : an official journal of the American Association for Cancer Research, 7(7), 1932–1936.
https://pubmed.ncbi.nlm.nih.gov/11448906/
45. Poon, R. T., Lau, C. P., Cheung, S. T., Yu, W. C., & Fan, S. T. (2003). Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer research, 63(12), 3121–3126.
https://pubmed.ncbi.nlm.nih.gov/12810638/
46.Shang, Z. J., Li, J. R., & Li, Z. B. (2002). Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma. International journal of oral and maxillofacial surgery, 31(5), 495–498.
https://doi.org/10.1054/ijom.2002.0284
47.Gorski, D. H., Leal, A. D., & Goydos, J. S. (2003). Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression. Journal of the American College of Surgeons, 197(3), 408–418.
https://doi.org/10.1016/S1072-7515(03)00388-0
48.Wartiovaara, U., Salven, P., Mikkola, H., Lassila, R., Kaukonen, J., Joukov, V., Orpana, A., Ristimäki, A., Heikinheimo, M., Joensuu, H., Alitalo, K., & Palotie, A. (1998). Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thrombosis and haemostasis, 80(1), 171–175.
https://pubmed.ncbi.nlm.nih.gov/9684805/
